Impact of Concomitant Methotrexate Use and Prior Biologic Disease‐Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial
Objective We evaluate tofacitinib efficacy and safety in patients with juvenile idiopathic arthritis (JIA) stratified by concomitant methotrexate and prior biologic disease‐modifying antirheumatic drug (bDMARD) treatment. Methods In this two part, double‐blind, randomized withdrawal Phase 3 trial (N...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley
2025-10-01
|
| Edice: | ACR Open Rheumatology |
| On-line přístup: | https://doi.org/10.1002/acr2.70097 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
